Investor Presentation

Investor Presentation - September 2026 - FY26 revenue USD 1Bn+ (INR 92,035 Mn), +16.6% y-y; PAT growth 33.1%, margin +120 bps y-y - Domestic revenue INR 40,270 Mn, +10.0% y-y; chronic therapies now 60%+ of mix - International revenue INR 51,766 Mn, +22.2% y-y; Europe +25.5%, Canada +18.7%, RoW +21.8% - EBITDA margin improved to 19.4% (+80 bps y-y); strong operational leverage - FY27 focus on deepening anaemia franchise, scaling cardio-metabolics, CNS, super-specialty - R&D investment at 4.2% of revenue; pipeline includes complex injectables, biologics, ADCs - Manufacturing scale with 13 facilities, compliant with global regulatory standards - Sustainability: 64.7% renewable power, 8.5% reduction in Scope 2 emissions FY26 - Q1 FY27 revenue INR 25,804 Mn, +22.8% y-y; PAT margin improved to 11.3% - Net debt INR 10,538 Mn; capex INR 3,606 Mn in FY26 supporting growth